| Literature DB >> 28581362 |
Lu Han1,2, Wen-Jun Shen1,2, Stefanie Bittner1, Fredric B Kraemer1,2, Salman Azhar1,2.
Abstract
The PPARs are a subfamily of three ligand-inducible transcription factors, which belong to the superfamily of nuclear hormone receptors. In mammals, the PPAR subfamily consists of three members: PPAR-α, PPAR-β/δ and PPAR-γ. PPARs control the expression of a large number of genes involved in metabolic homeostasis, lipid, glucose and energy metabolism, adipogenesis and inflammation. PPARs regulate a large number of metabolic pathways that are implicated in the pathogenesis of metabolic diseases such as metabolic syndrome, Type 2 diabetes mellitus, nonalcoholic fatty liver disease and cardiovascular disease. The aim of this review is to provide up-to-date information about the biochemical and metabolic actions of PPAR-β/δ and PPAR-γ, the therapeutic potential of their agonists currently under clinical development and the cardiovascular disease outcome of clinical trials of PPAR-γ agonists, pioglitazone and rosiglitazone.Entities:
Keywords: NAFLD; PPAR-β/δ agonist; PPAR-γ agonist; Type 2 diabetes; cardiovascular disease; hyperglycemia; hyperinsulinemia; lipid and glucose metabolism; metabolic syndrome
Mesh：
Substances：
Year: 2017 PMID： 28581362 PMCID： PMC5941699 DOI： 10.2217/fca-2017-0019
Source DB: PubMed Journal: Future Cardiol ISSN： 1479-6678